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The National Kidney Foundation/Kidney-Dialysis Outcome
Quality Initiative guidelines recommend to maintain the serum
intact parathyroid hormone (PTH) concentration between 150
and 300 ng/l in chronic kidney disease (CKD) stage 5 patients.
As these limits were derived from studies that used the Allegro
intact PTH assay, we aimed to evaluate whether they were
applicable to other PTH assays. We compared the PTH
concentrations measured with 15 commercial immunoassays
in 47 serum pools from dialysis patients, using the Allegro
intact PTH assay as the reference. We also evaluated the
recovery of graded amounts of synthetic 1–84 and 7–84 PTH
added separately to a serum pool. Although the assays were
highly correlated, the concentrations differed from one assay
to another. The median bias between the tested assays and
the Allegro intact PTH assay ranged from 44.9 to 123.0%.
When the PTH concentrations were 150 or 300 ng/l with the
Allegro intact PTH assay, they ranged with other assays
from 83 to 323 ng/l and from 160 to 638 ng/l, respectively.
The tested assays recognized 7–84 PTH with various
cross-reactivities, whereas a given amount of 1–84 PTH was
recovered differently by these assays. We found important
inter-method variability in PTH results owing to both antibody
specificity and standardization reasons. The unacceptable
consequence is that opposite therapeutic attitudes may be
reached in a single patient depending on the PTH assay used.
We propose to use assay-specific decision limits for CKD
patients, or to apply a correcting factor to the PTH results
obtained with a given assay.
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Bone disorders associated with chronic kidney disease (CKD)
are globally termed renal osteodystrophy, and range from
high-turnover bone diseases, such as osteitis fibrosa cystica to
low-turnover bone diseases, such as adynamic bone disease.
Assessing renal osteodystrophy subtypes is specially impor-
tant for the therapeutic decision during the follow-up of
CKD patients. Indeed, treatments that decrease serum
parathyroid hormone (PTH) levels, such as calcium salts/
active vitamin D analogs or calcimimetics, are advised in case
of secondary hyperparathyroidism and high-turnover bone
diseases, whereas abstention is the rule in case of low serum
PTH levels and low-turnover bone diseases. The gold
standard method to assess renal osteodystrophy is the
histomorphometric evaluation on iliac crest bone biopsies
obtained after double tetracycline labelling. However, this
invasive and complicated method cannot be used in daily
practice, and alternative methods are thus routinely needed.
In this setting, PTH measurement is performed worldwide
and the physicians rely on the National Kidney Foundation/
Kidney-Dialysis Outcome Quality Initiative (NKF/K-DOQI)
recommendations1 to maintain their patients’ serum PTH
level within a range of values defined according to the stage of
CKD. For example, the recommended PTH target range in
CKD stage 5 patients is 150–300 ng/l. However, when a
diagnosis or a therapeutic decision is based on unique
biological cutoff values, a frequent problem arises from the
assay-dependent variability of the biological measurement.
The target serum PTH intervals recommended in the NKF/
K-DOQI guidelines have been derived from studies2–4 that
compared, in dialyzed patients, histomorphometric data with
serum PTH concentrations measured with the Allegro assay
from Nichols Institute Diagnostics Inc., the first one of the
so-called ‘intact’ PTH assays.5 In the present study, we aimed
to evaluate whether these recommended serum PTH target
ranges were applicable to every PTH assay available in France
and in most Western countries, and, if necessary, to provide
equivalences between the various assays, using the Allegro
assay as a reference. We also evaluated the recovery by the
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various PTH assays of known amounts of synthetic 1–84 and
7–84 PTH in order to assess whether the possible inter-
method discrepancies were owing to a problem of calibra-
tion, antibody specificity, or both (Table 1).
RESULTS
Assay comparison
Using the Allegro intact PTH assay, the median PTH
concentration in the 47 serum pools was 233 ng/l and ranged
from 10 to 1191 ng/l. Considering the PTH concentrations
measured in these 47 pools, the equations of the weighted
Deming regression lines between the Allegro Nichols assay (X)
and the other 14 assays (Y) are presented in Table 2. Each of
the other 14 assays correlated highly with the Allegro intact
PTH assay (r value ranging from 0.975 to 0.994). However, the
comparison also revealed a wide range of difference between
the results obtained with the Allegro intact PTH assay and
those provided by the other assays. Using the above-mentioned
equations, we calculated for each assay, the equivalent
concentration when serum PTH concentration was 150, 300,
and 1000 ng/l with the Allegro intact PTH assay (Table 3).
When the serum PTH concentration was 150 or 300 ng/l with
the Allegro intact PTH assay, it ranged with the other assays
from 83 to 323 ng/l and from 160 to 638 ng/l, respectively.
Recovery of synthetic PTH peptides
Recovery of synthetic 1–84 and 7–84 PTH is indicated in
Table 4 for each method. These results confirmed that both
third-generation assays did not measure 7–84 PTH. Whereas
some of the second-generation (‘intact’) assays measure 1–84
and 7–84 PTH similarly, others only measured a fraction of
7–84 PTH as evidenced in Table 4.
DISCUSSION
The NKF/K-DOQI guidelines recommend to maintain the
serum intact PTH concentration between 150 and 300 ng/l in
CKD stage 5 (either dialyzed or not) patients.1 As pointed
out in the introduction, these limits have been derived from
studies that compared bone biopsy data to serum PTH
concentrations measured with the Nichols Allegro intact
PTH assay.2–4 This is the reason why we used this assay as the
reference in the present study, although, from an analytical
point of view, it cannot be considered as the reference
Table 1 | Some characteristics of the PTH assays tested in the present study as provided by the manufacturers
Name of the
assay Manufacturer
2nd or 3rd
generation Automated Tracer
Epitope of
coated Ab
Epitope of
labelled Ab
Detection
limit (ng/l)
Highest
measurable
value (ng/l)
Intra-assay
CV (%)
Inter-assay
CV (%)
Normal
range
(ng/l)
Assay
performed in
the lab of
Allegro-intact
PTH
Nichols Institute (San
Clemente, CA, USA)
2nd No 125-I 39–84 1–34 5.0 1815 o3.4 o5.6 10–65 CM
N-tact PTH IRMA DiaSorin (Stillwater, MN, USA) 2nd No 125-I 39–84 1–34 0.7 2000 2.7 4.3 13–54 MM
PTH IRMA
Immunotech
Beckman-Coulter (Marseille,
France)
2nd No 125-I Not
specified
Not
specified
2.0 2600 7.5 11 10–65 MCC
ELISA-PTH Schering-Cis Bio (Gif sur
Yvette, France)
2nd No 125-I 39–84 1–34 3.0 1500 o4.3 o3.4 11–62 DC
Total-intact PTH
IRMA
Scantibodies Laboratories
(Santee, CA, USA)
2nd No 125-I 39–84 1–34 1.2 2456 o5.0 o7.0 14–66 GC
DSL PTH IRMA DSL (Webster, TX, USA) 2nd No 125-I 39–84 1–34 6.0 2000 2.8 3.6 9–55 MM
DSL PTH ELISA DSL (Webster, TX, USA) 2nd No Alkaline
phosphatase
Not
specified
Not
specified
1.0 2000 5.5 6.2 16.62 MM
Elecsys PTH Roche Diagnostics (Meylan,
France)
2nd Yes Ruthenium 26–32 55–64 1.2 5000 o5.4 o7.1 15–65 EP
Immulite 2000-
intact PTH
DPC (Los Angeles, CA, USA) 2nd Yes Alkaline
phosphatase
44–84 1–34 3.0 2500 o5.7 o8.8 11–67 At DPC by JCS
PTH-ACS 180 Bayer (Tarrytown, NY, USA) 2nd Yes Acridinium
ester
39–84 1–34 1.5 1900 o4.1 o4.6 14–72 DC
PTH
AdviaCentaur
Bayer (Tarrytown, NY, USA) 2nd Yes Acridinium
ester
39–84 1–34 2.5 1900 o5.2 o5.8 14–72 CM
Intact PTH
advantage
Nichols Institute (San
Clemente, CA, USA)
2nd Yes Acridinium
ester
39–84 1–34 1.0 1800 o6.7 o9.2 10–65 XP
LIAISON N-tact
PTH
DiaSorin (Stillwater, MN, USA) 2nd Yes Isoluminol 39–84 1–34 1.0 2000 o4.8 o5.9 17.3–72.9 ELB
Ca-PTH IRMA Scantibodies Laboratories
(Santee, CA, USA)
3rd No 125-I 39–84 1–4 1.0 2190 o5.0 o8.0 5–39 GC
BioIntact PTH
advantage
Nichols Institute (San
Clemente, CA, USA)
3rd Yes Acridinium
ester
39–84 1–5 1.5 1800 o5.5 o8.7 8–50 XP
DSL, diagnostic system laboratories; ELISA, enzyme-linked immunosorbent assay; IRMA, immunoradiometric assay; PTH, parathyroid hormone.
The intra- and inter-assay CVs are for concentrations 410 ng/l. The right column identifies the member of our group (initials) who performed the assay.
Table 2 | Equations of the weighted Deming regression lines
between the Allegro-intact PTH assay (X) and the 14 other
methods (Y)
Assay
95% CI
of slope
95% CI
of intercept
N-tact PTH IRMA=0.51 Allegro+6.5 0.48; 0.55 3.4; 9.5
PTH IRMA Immunotech=1.21 Allegro+6.1 1.14; 1.28 0.5; 12.7
ELISA-PTH=0.94 Allegro+7.7 0.89; 0.99 5.2; 10.2
Total intact PTH IRMA=0.85 Allegro+6.6 0.80; 0.89 3.8; 8.3
DSL PTH IRMA=2.10 Allegro+8.1 1.96; 2.24 5.3; 21.5
DSL PTH ELISA=1.73 Allegro+4.2 1.56; 1.9 8.2; 16.7
Elecsys PTH=1.0 Allegro+11.3 0.95; 1.04 9.4; 13.3
Immulite 2000 Intact PTH=1.32 Allegro+13.9 1.25; 1.39 11.2; 16.5
PTH-ACS 180=1.26 Allegro–3.9 1.08; 1.43 22.4; 14.7
PTH AdviaCentaur=1.16 Allegro 6.2 0.95; 1.36 27.8; 15.4
Intact PTH advantage 1.10 Allegro+8.9 1.04; 1.14 6.0; 11.9
LIAISON N-tact PTH=0.75 Allegro–1.9 0.68; 0.81 8.5; 4.7
Ca-PTH IRMA=0.54 Allegro+2.6 0.50; 0.57 1.1; 4.1
BioIntact PTH advantage=0.70 Allegro+4.2 0.64; 0.76 2.4; 10.9
CI, confidence interval; DSL, diagnostic system laboratories; ELISA, enzyme-linked
immunosorbent assay; IRMA, immunoradiometric assay; PTH, parathyroid hormone.
The PTH concentrations (ng/l) were obtained in 47 serum pools made of serum of
dialysis patients.
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method to measure serum PTH concentration. We demon-
strate here that the NKF/K-DOQI-recommended limits are
not applicable independently of the knowledge of the PTH
assay used. The practical implication of this finding is that, in
CKD stage 5 patients, the decision to initiate, to maintain, or
to stop a PTH-lowering treatment such as an active vitamin
D analog or a calcimimetic, may highly depend on the PTH
assay used. This is definitely not acceptable, as opposite
therapeutic decisions may be reached in a single patient
depending on the PTH assay used. Similarly, it cannot be
excluded that the decision to recommend parathyroidectomy
in CKD patients may be influenced by this inter-method
variability, as suggested recently.8 We must underline that two
of the tested assays, the diagnostic system laboratories (DSL)
immunoradiometric assay and enzyme-linked immuno-
sorbent assay, provided considerably higher results than the
other 13 assays and could thus be considered as outliers.
Excluding these two assays from the analysis would reduce
the influence that the inter-method variability in PTH
measurement might have on clinical decision making.
However, among the remaining 13 methods, those which
provided the lowest and the highest results, the N-tact PTH
immunoradiometric assay and the Immulite 2000 intact PTH
assay, respectively, still differed by a factor 42.5. These two
methods are second-generation assays largely used world-
wide.
The reasons for these inter-method discrepancies are
probably multiple. Circulating PTH is a mixture of different
molecules. Besides the intact 1–84 PTH molecule, C-terminal
fragments,9 which are not recognized by any of the assays
tested in the present study, N-terminal-truncated PTH
fragments also termed non-1–84 PTH,6 and a recently
discovered PTH species termed amino-PTH (N-PTH)10 are
present in various proportions in the serum of patients. A
recent paper has elucidated the nature of the N-terminal-
truncated fragments.6 They consist in distinct molecules, the
longest one starting in position 4 (4–84 PTH) and the
shortest one starting in position 15 (15–84 PTH), whereas the
most abundant is 7–84 PTH. Our data show that the different
second-generation (‘intact’) PTH assays recognize synthetic
7–84 PTH with various degrees of cross-reactivity as reported
previously with some assays11 and, more largely, by the UK
quality control NEQAS (http://www.ukneqas.org.uk/pth7_
84ag2001.pdf), as summarized in Martin and Olgaard,12
whereas the third-generation assays do not recognize this
molecule. The exact structure of N-PTH is still unknown, but
it has been hypothesized that it could be 1–84 PTH
phosphorylated on the serine residue 17.10 Whereas this
molecule represents usually 10% of the largest circulating
PTH molecules, it is overproduced in some patients with
parathyroid carcinoma,13 severe secondary,14 or primary
hyperparathyroidsm.15 Although not tested in the present
study, it has previously been shown that N-PTH is measured
by the third-generation assays and by some second-genera-
tion assays that use a distal anti-N-terminal antibody, such as
the Elecsys assay, but not by second-generation assays that
uses a proximal anti-N-terminal antibody, such as the
Allegro- and the Total intact Scantibodies assays.16 In
addition, the percentage of non-1–84 PTH (such as 7–84
PTH) has been found to vary from one patient to
another,17,18 and some groups have observed that it increases
when the glomerular filtration rate decreases, reaching a
Table 3 | Equivalent concentrations obtained with each PTH
assay, when the value measured with the Allegro assay is
150, 300, or 1000 ng/l
Assay
PTH
(ng/l)
PTH
(ng/l)
PTH
(ng/l)
Median
bias (%)
Allegro intact PTH 150 300 1000 0
N-tact PTH IRMA 83 160 517 44.9 (68.0; 26.2)
PTH IRMA Immunotech 188 369 1216 23.9 (6.1; 108.3)
ELISA-PTH 149 290 948 1.6 (24.3; 47.2)
Total intact PTH IRMA 134 262 857 14.5 (41.5; 23.5)
DSL PTH IRMA 323 638 2108 123.0 (53.1; 188.9)
DSL PTH ELISA 264 523 1734 79.6 (8.0; 180.9)
Elecsys PTH 161 311 1011 7.3 (13.8; 80.3)
Immulite 2000 intact PTH 212 410 1334 37.8 (3.8; 130.8)
PTH-ACS 180 185 374 1256 18.8 (9.9; 69.4)
PTH AdviaCentaur 168 342 1154 9.5 (27.6; 55.6)
Intact PTH advantage 174 339 1109 14.6 (10.4; 72.2)
LIAISON N-tact PTH 111 223 748 23.4 (68.2; 1.9)
Ca-PTH IRMA 84 165 543 44.8 (65.6; 22.8)
BioIntact PTH advantage 109 214 704 27.6 (53.0; 12.5)
DSL, diagnostic system laboratories; ELISA, enzyme-linked immunosorbent assay;
IRMA, immunoradiometric assay; PTH, parathyroid hormone.
These values were calculated according to the equations presented in Table 2. The
median bias value (right column), expressed in %, is, for a given method (A), the
median (minimum–maximum) of the ratios, ((value measured with A–value
measured with the Allegro assay)/value measured with the Allegro assay) in the
47 serum pools. As we considered the Allegro-intact PTH as the reference, the bias
with this method is, by definition, 0.
Table 4 | Recovery of synthetic 1–84 and 7–84 PTH
Assay
Recovery
of synthetic
1–84 PTH
(%)
Recovery of
synthetic
7–84 PTH
(%)
Recovery
7–84 PTH
Recovery
1–84 PTH
Allegro-intact PTH 86.872.4 85.075.9 0.98
N-tact PTH IRMA 82.171.5 47.271.2 0.57
PTH IRMA Immunotech 97.173.5 80.573.9 0.83
ELISA-PTH 89.673.0 62.672.5 0.70
Total intact PTH IRMA 81.772.2 70.471.0 0.86
DSL PTH IRMA 215.677.5 104.4711.1 0.48
DSL PTH ELISA 112.177.5 127.671.0 1.14
Elecsys PTH 71.472.2 66.272.1 0.93
Immulite 2000 intact PTH 105.271.4 60.373.9 0.57
PTH-ACS 180 102.570.7 82.971.9 0.81
PTH AdviaCentaur 106.270.1 87.673.3 0.82
Intact PTH advantage 102.470.7 82.571.9 0.81
LIAISON N-tact PTH 111.472.4 76.673.2 0.67
Ca-PTH IRMA 63.171.7 0 0
BioIntact PTH advantage 90.270.7 0 0
DSL, diagnostic system laboratories; ELISA, enzyme-linked immunosorbent assay;
IRMA, immunoradiometric assay; PTH, parathyroid hormone.[2]The ratio of the
recovery of both compounds (right column) indicates whether a given assay, inde-
pendently of the absolute recovery values, measures similarly both molecules. A ratio
of 1 indicates a similar recognition of 1–84 and 7–84 PTH, whereas a ratioo1 indicates
that the assay cross-reacts with 7–84 PTH less than with 1–84 PTH. Data are
mean7s.e. of the recovery of five different amounts of synthetic PTH.
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mean 50% in dialyzed patients.19 Thus, third- and second-
generation PTH assays, especially those that fully recognize
7–84 PTH, may, in some patients, provide divergent
informations. Taken together, these data argue for an
implication of the variable antibody specificity in these
inter-method discrepancies.
No conclusion regarding the respective clinical interest of
the second- and the third-generation assays can be derived
from our results. In particular, it cannot be concluded that
second- and third-generation PTH assays provide the same
information in CKD stage 5 patients. Indeed, each of our
serum pools was obtained by mixing several (10–20) serum
samples from dialyzed patients. Thus, even if individual
patients may have variable percentages of non-1–84 PTH, it
was expected that our 47 pools contained similar percentages
of these fragments. Although the respective performances of
the third- and the second-generation assays in the manage-
ment of CKD patients is still a matter of debate,20–24 these
assays are now largely used worldwide. The NKF/K-DOQI
guidelines acknowledge that the third-generation PTH assays
provide lower values than the second-generation (‘intact’)
assays, and these recommendations suggest that the target
PTH concentration to be maintained in CKD stage 5 patients
with these new assays is approximately half of that
recommended for the ‘intact’ assays (i.e. 75–150 ng/l instead
of 150–300 ng/l). Our data are quite in agreement with this
statement when we consider the third-generation assay from
Scantibodies Laboratories Inc., but not when we consider the
Bio-Intact Nichols assay. Indeed, contrary to what was
reported by some authors,12 we find, like others,25–27 that
these two third-generation assays do not provide exactly the
same results. One reason to explain this discrepancy may be
that the manufacturers may modify the calibration of their
kit, sometimes without providing a clear information to their
customers (Cantor28 and personal opinion of all members of
our group). Although we agree with the opinion that the
third-generation PTH assays are an opportunity to standar-
dize PTH results (as they measure the same molecules), our
results suggest that this was not yet achieved at the moment
we performed the assays.
As introduced above, a second reason for the inter-
method discrepancies relates to the lack of standardization of
PTH assays as evidenced by our results and previous
reports.16 Indeed, although the recovery values reported in
Table 4 cannot be considered as the absolute truth as they are
based on Bachem’s estimates of the mass of synthetic PTH
and on our dilution procedure on the one hand, and as
various synthetic PTH preparations may be recovered
differently by the same assay (JC Souberbielle and P
Houillier, personal unpublished results) on the other hand,
our results demonstrate that a same amount of synthetic 1–84
PTH diluted in the same volume of serum is not recovered
similarly by the various assays. The only reference prepara-
tion for PTH immunoassays, identified as WHO 79/500, was
prepared in 1981 with purified human PTH,29 and none of
the PTH assays tested in the present study has been calibrated
against this standard. In fact, PTH immunoassays are usually
calibrated against synthetic 1–84 PTH of various origins, and
no recognized international standard made of synthetic PTH
is currently available. If such a standard becomes available, a
possible matrix effect30 as well as the instability of synthetic
PTH over extended storage periods31 will have to be taken
into account in the recalibration procedure. It must be
stressed that even if the standardization of all PTH assays
against a same international standard should reduce the
inter-method variability, it cannot be expected, owing to the
above-mentioned variability in antibody recognition, that
every assay will provide the same serum concentration value.
Assuming this, using assay-specific decision thresholds (such
as proposed in Table 3) or correcting the concentrations
measured with a given assay by a specific factor (e.g., the
inverse of the slopes reported in Table 2, or the inverse of the
bias presented in Table 3) would help to better interpret a
PTH concentration with regards to the NKF/K-DOQI
recommendations. Finally, another point that may induce
discrepancies between assay results must be mentioned.
Indeed, differences up to 20–25% between PTH concentra-
tions measured in serum and in ethylenediaminetetraacetic
acid plasma samples have been reported with some
assays.32,33 Whether the inter-method variability found with
serum samples in the present study would have been similar
if ethylenediaminetetraacetic acid samples were used is a
question that deserves further evaluation. Nevertheless, we
think that recommendations on the nature of the blood
sample (serum or ethylenediaminetetraacetic acid samples)
used to measure PTH in CKD patients should appear in
future updating of the NKF/K-DOQI. We must underline
that our results are a photography of the discrepancies
between the PTH assays available in France at a given
moment. As mentioned above, the calibration of a given
assay may change over time, and new assays may become
available. We believe that it is important to regularly question
whether the PTH concentration values obtained in a
laboratory fit well with the NKF/K-DOQI recommendations,
and, if necessary, to adjust the values.
In conclusion, we show important inter-method variation
in PTH results. As a consequence, the therapeutic decision
based on unique cutoff levels such as those recommended in
the NKF/K-DOQI guidelines may depend on the PTH assay
used. As this is not acceptable, we propose either to use assay-
specific decision thresholds or to apply a specific correction
factor to the measured PTH concentrations. This would
allow a more consistent interpretation of a PTH concentra-
tion with regards to the NKF/K-DOQI recommendations.
MATERIALS AND METHODS
Samples
As our main goal was to measure PTH concentration in serum of
CKD patients, with 15 different assays, we had to pool several sera to
obtain the required number (47) of 9 ml serum samples. The 47
serum pools were prepared by six members of our group (10 pools
by JCS and ELB, five pools by MCC, seven pools by GC, five pools
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by MM, eight pools by XP, and 12 pools by EP) to obtain graded
PTH concentrations. The sera used to prepare these pools were all
obtained from adult hemodialyzed patients and were chosen
according to their PTH concentration, which had to cluster around
a target value for a given pool. We ensured that each serum used in
the pools was from hemodialyzed patient and we did not record any
further information on the patient status. The number of sera per
pool depended on the available volume of serum and ranged from
10 to 20. In each of the six laboratories where the pools were
prepared, the procedure was the same, as was the time the samples
stayed at room temperature. The serum samples, which had been
kept frozen (201C) after the initial routine measurement of PTH
(they had thus been thawed once), were thawed, immediately mixed
together, and centrifugated at 3000 r.p.m. Each pools was then
fractionated into 0.6 ml aliquots, and all aliquots were stored at
201C in polypropylene tubes. Then, using the facility (a
refrigerator van) of Pasteur Cerba laboratory, they were carried on
dry ice to the laboratory of JCS (at Necker hospital) where they were
stored at 201C. In addition, we prepared another pool (150 ml)
made of sera kept frozen (201C) for less than 3 months in the lab
of JCS, and obtained from patients (80 osteoporotic women aged
50–69 years, in whom a secondary cause of low bone mass had been
excluded) with a normal renal function (estimated creatinine
clearance 480 ml/mn) and a normal serum PTH concentration.
This non-CKD pool was fractionated into 11 aliquots of 12.5 ml
each. Its PTH concentration was 32 ng/l (mean of four replicates)
when measured with the Allegro intact PTH assay. We purchased
synthetic 1–84 PTH (Ref. H-1370, Bachem, Bubendorf, Switzerland)
and synthetic 7–84 PTH (Ref. H-3084, Bachem, Bubendorf,
Switzerland). These recombinant peptides had exactly the same
amino-acid sequence than the human natural peptides and have
been used by others.6 In a single laboratory (Necker hospital), we
added five increasing amounts of synthetic 1–84 PTH to five aliquots
of the non-CKD pool, and the five same amounts of synthetic 7–84
PTH to five other aliquots (spiked specimens). Briefly, our dilution
procedure was as follows. The 1–84 PTH powder (100 mg) and the
7–84 PTH powder (500 mg) were diluted each in 1 ml of a serum
obtained from a single patient with a post-thyroidectomy hypopar-
athyroidism (PTH level at 3 ng/l with the Allegro intact assay). These
two concentrated serum solutions (100 m/ml of 1–84 PTH and
500mg/ml of 7–84 PTH) were separately diluted in a phosphate
buffer (1% bovine serum albumin) to a concentration of 10 ng/ml
(solution A for 1–84 PTH and solution F for 7–84 PTH). Solution A
and solution F were then serially diluted 1:2 in the same buffer
(solutions B, C, D, and F for 1–84 PTH and solutions G, H, I, and J
for 7–84 PTH). The concentrations were thus 5 ng/ml for solutions B
and G, 2.5 ng/ml for solutions C and H, 1.25 ng/ml for solutions D
and I, and 0.625 ng/ml for solutions E and J. Finally, 100 ml were
removed from ten 12.5 ml aliquots of the non-CKD pool, and were
replaced by 100 ml of solutions A–J. This constituted the 10 spiked
specimens, which were fractionated into 0.6 ml aliquots and kept
frozen (201C). The last aliquot of the non-CKD pool was used to
measure the basal PTH level with each tested assay. Its concentration
was taken into account in the calculation of the recovery of the PTH
peptides. In the spiked specimens, the theoretical concentrations of
the synthetic compounds were thus 800, 400, 200, 100, and 50 ng/l,
respectively. Using again the Pasteur Cerba Laboratory refrigerator
van, plastic bags, each one containing one aliquot of every 47 CKD
pools and one aliquot of each of the spiked and basal non-CKD pool
(one bag per assay method) were carried to the laboratories, which
performed the immunoassays (see the list in Table 1) where they
were stored frozen (201C) until assayed. Thus, the samples tested
were exactly the same from one method to another, and were
assayed with every method under the same storage conditions. All
laboratories were blinded to the expected PTH concentrations and
to the sample status (i.e. basal or spiked).
PTH assays
We tested the 15 different commercial PTH assays available in
France for routine clinical use (Table 1). Seven were immunoradio-
metric assays, one was a manual immunoenzymology assay
(enzyme-linked immunosorbent assay), and seven were automated
immunometric assays. Two out of the 15 assays tested were third-
generation assays, the CAP assay from Scantibodies laboratories Inc.
(Santee, CA, USA) and the Bio-Intact Advantage PTH assay from
Nichols Institute Diagnostics (San Clemente, CA, USA), whereas the
others were second-generation assays, also termed ‘intact’ PTH
assays. Assay characteristics, as provided by their respective
manufacturers, are presented in Table 1.
Expression of results and statistical analysis
We used the weighted Deming regression method to assess the
relationship between the values provided by the Allegro PTH assay
(X) and the values provided by each of the other 14 assay (Y) as
recommended.7 By means of these equations, we calculated the
equivalent concentration for each assay method when PTH
concentration was 150, 300, and 1000 ng/l with the Allegro assay.
The recovery of synthetic 1–84 and 7–84 PTH was evaluated as the
ratio of the measured concentration to the expected concentration.
In pools spiked with 7–84 PTH, we took into account in the
calculation of the expected concentration, the fact that the molar
mass of 7–84 PTH (8781 kDa) is lower than the molar mass of 1–84
PTH (9425 kDa). Statistical analyses were performed using the
Statview software (SAS, Cary, NC, USA).
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